ResMed (NYSE:RMD – Get Free Report) issued its quarterly earnings data on Thursday. The medical equipment provider reported $2.86 EPS for the quarter, topping the consensus estimate of $2.82 by $0.04, FiscalAI reports. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion.
ResMed Stock Up 0.8%
Shares of NYSE:RMD traded up $1.66 during trading hours on Thursday, reaching $213.59. The stock had a trading volume of 1,885,490 shares, compared to its average volume of 1,088,324. ResMed has a 1 year low of $210.60 and a 1 year high of $293.81. The firm’s 50 day moving average is $234.21 and its 200-day moving average is $246.92. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. The stock has a market capitalization of $31.12 billion, a price-to-earnings ratio of 21.13, a P/E/G ratio of 1.46 and a beta of 0.93.
Insider Buying and Selling
In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $225.50, for a total value of $1,125,470.50. Following the sale, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $105,133,286.50. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 21,023 shares of company stock worth $5,230,857. Insiders own 0.65% of the company’s stock.
Institutional Investors Weigh In On ResMed
ResMed News Roundup
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: Quarterly results beat expectations — ResMed reported EPS of $2.86 vs. $2.82 consensus and revenue of $1.43B (vs. $1.42B est.). The beat on both EPS and revenue supports the stock’s upward move. View Press Release
- Positive Sentiment: Operating performance improved — GAAP gross margin rose ~290 bps to 62.2% (non?GAAP 62.8%), GAAP operating income +17% and non?GAAP operating income +18%. Strong margins and a 27.5% net margin signal durable profitability that helps justify current multiples. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
- Positive Sentiment: Strong cash flow and shareholder returns — Operating cash flow of $554M with $262M returned through buybacks and dividends supports capital-return policies and reduces downside risk. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
- Neutral Sentiment: CFO transition announced — Longtime CFO Brett Sandercock will retire effective May 4; Aaron Bloomer has been named successor after a comprehensive search. The planned succession and internal appointment reduce disruption risk but investors will monitor execution. Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
- Neutral Sentiment: Analyst/pre?earnings coverage and thematic pieces — Recent articles examine key metrics, profit forecasts and the potential re?rating tied to sleep?apnea tailwinds; these frame investor expectations but don’t change fundamentals immediately. Did Stronger Profit Forecasts and Sleep Apnea Tailwinds Just Shift ResMed’s (RMD) Investment Narrative?
- Neutral Sentiment: Investor event — Management is hosting a conference call/webcast (noted in the release); guidance commentary and Q&A from the call are likely near?term drivers for further stock moves. Investor Webcast
Analyst Upgrades and Downgrades
RMD has been the topic of several recent analyst reports. Royal Bank Of Canada upped their price objective on shares of ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Stifel Nicolaus increased their target price on shares of ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a report on Friday, January 30th. Robert W. Baird set a $281.00 target price on shares of ResMed in a report on Friday, January 30th. Wall Street Zen lowered shares of ResMed from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Piper Sandler increased their target price on shares of ResMed from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.55.
View Our Latest Stock Analysis on ResMed
ResMed Company Profile
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
See Also
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
